MedPage Today) — There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial.
An established cardiac myosin inhibitor for hypertrophic cardiomyopathy…
Read More